66 (1) (2)

45

31

21

14

No. of the second

6.5

Fig. 1A

66 (1)

(2)

200 J. Bur

(3)

(4)

45

31

21


14

6.5

Fig. 1B 3 C 2.5 SBR 2 **L**T-**П**а OD 1.5 1 0.5 0 300 150 75 19 38 8.5 600

Concentration (ng/ml)


Fig. 1C



<u>Immunogen</u>

- ☐ Sham-immunized
- **⊠** SBR
- III SBR-CTA2/B
- SBR-LT-IJaA2/B

Fig. 2A



<u>Immunogen</u>

- ☐ Sham-immunized
- SBR
- SBR-CTA2/B
- SBR-LT-IIaA2/B

Fig. 2B





Fig. 3C



Immunogen/ Group

- SBR-CTA2/B
- ☑ SBR-LT-HaA2/B

Fig. 4A




Fig. 4B

Immunogen/Group

- SBR-CTA2/B
- SBR-LT-IIaA2/B

Immunogen/Group

☑ SBR-CTA2/B

SBR-LT-IIaA2/B




Fig. 4C

Immunogen/Group

SBR-CTA2/B

☑ SBR-LT-IIaA2/B




Fig. 4D




Fig. 5A





Fig. 5B



- non-stimulated
- anti-CD3
- \mathbf{CT}
- LT-IIa
- LT-IIb

Fig. 6A





Fig. 6B

- non-stimulated
- anti-CD3
- \mathbf{CT}
- LT-IIa
- LT-IIb



- mon-stimulated
 - □ anti-CD3
- anti-CD3 + CT
- ☐ anti-CD3 + LT-IIa
- ☑ anti-CD3 + LT-IIb

Fig. 6C




Fig. 6D




Fig. 6E

anti-CD3

CT

LT-IIa

LT-IIb

Time (hr)

Fig. 7




Fig. 8A




Fig. 8B




Fig. 8C




Fig. 8D